Mina Kim Sells 17,986 Shares of Acelyrin, Inc. (NASDAQ:SLRN) Stock

Acelyrin, Inc. (NASDAQ:SLRN) CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the sale, the chief executive officer now owns 671,753 shares in the company, valued at approximately $1,840,603.22. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Acelyrin Trading Down 0.7 %

Shares of SLRN opened at $2.77 on Friday. The business’s 50-day moving average price is $2.27 and its 200 day moving average price is $3.83. The stock has a market capitalization of $277.90 million, a P/E ratio of -1.13 and a beta of 1.25. Acelyrin, Inc. has a 1-year low of $1.85 and a 1-year high of $8.39.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. On average, research analysts predict that Acelyrin, Inc. will post -2.53 earnings per share for the current year.

Hedge Funds Weigh In On Acelyrin

Several institutional investors and hedge funds have recently bought and sold shares of SLRN. XTX Topco Ltd purchased a new position in Acelyrin during the 4th quarter valued at about $33,000. 4WEALTH Advisors Inc. purchased a new position in Acelyrin during the 4th quarter valued at about $35,000. Hsbc Holdings PLC purchased a new position in Acelyrin during the 4th quarter valued at about $36,000. RPO LLC purchased a new position in Acelyrin during the 4th quarter valued at about $46,000. Finally, Virtu Financial LLC purchased a new position in Acelyrin during the 3rd quarter valued at about $50,000. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SLRN shares. HC Wainwright dropped their price target on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Citigroup dropped their price target on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company dropped their price target on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Acelyrin has a consensus rating of “Hold” and an average price target of $9.60.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.